DNMT3A and acute myeloid leukemia: Viability of primary AML cells was reduced in the presence of ATRA or SAHA; however, AML cells with KMT2A-PTD/DNMT3A-WT were more sensitive to those drugs when compared with KMT2A-PTD/DNMT3A-MT AML cells (Fig. 2f).